Rivaroxaban Impurity是一种rivaroxaban的杂质，用于确保药物纯度和研究其影响。

Edoxaban impurity 4是 Edoxaban 的一种杂质。Edoxaban 是一种口服的选择性和有效的因子 Xa (FXa) 抑制剂，用于预防中风。

5-R-Rivaroxaban is an (R) enantiomer of rivaroxaban, an oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders.

Dechloro Rivaroxaban是一种口服活性高的选择性 Factor Xa 抑制剂，抑制游离 FXa 的 Ki 为 0.4 nM，能够有效抑制凝血酶原和纤维蛋白相关的 FXa 活性 (IC₅₀分别为 2.1 nM 和 92 nM)。

Asundexian是一种口服活性的 FXIa 抑制剂，通过有效、可逆地结合 FXIa 活性位点抑制其活性，IC₅₀ 为 1 nM。该化合物适用于血栓性疾病的治疗研究，特别是抗凝血药物的开发。

CH3OCO-D-CHA-Gly-Arg-pNA acetate是一种 factor Xa 的显色底物。

Betrixaban is a highly potent, selective, and orally efficacious factor Xa inhibitor with IC50 of 1.2 nM (inhibition of Factor 10a).

Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.

Fondaparinux sodium is a pentasaccharide inhibitor of antithrombin-dependent factor Xa (IC50 = 40 nM). It can bind to antithrombin III.

Darexaban is a potent and orally effective factor Xa inhibitor with IC50 value of 54.6nM.

Apixaban is a direct factor Xa inhibitor with an IC50 of 0.08 nM and 0.17 nM in human and rabbit, respectively.

Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.

Rivaroxaban is an inhibitor of factor Xa (FXa) with IC50 of 0.7 nM and Ki of 0.4 nM which developed for the treatment of thrombotic disease.